Saint George Hospital University Medical Center-SGHUMC, University of Balamand School of Medicine , Beirut, Lebanon.
Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine , Saint Louis, Missouri, USA.
Expert Opin Ther Targets. 2020 Sep;24(9):859-868. doi: 10.1080/14728222.2020.1790530. Epub 2020 Jul 13.
There is no cure for Alzheimer's disease (AD). One explanation may pertain to the need to intervene as early as possible upstream from the accumulation of β-amyloid plaques and tau tangles.
A PUBMED literature search was completed to review the biological or pathological changes at the basis of disease initiation; this includes neuroinflammation, oxidative stress, microbiome changes and glymphatic system dysfunction. Innovative therapeutic strategies based on these mechanisms are also discussed.
Improved understanding of the pathophysiological mechanisms that underly AD would assist in the identification of drug targets for clinical trials. Furthermore, pharmacokinetic and pharmacodynamic studies are key for the characterization of the properties of disease-modifying drugs and the improvement of their penetration of the blood-brain barrier. Drug targets can be examined at different stages of the disease, hence the importance of selecting and recruiting the appropriate participants, preferably at the earliest stage of AD. New trial designs should be established which primarily involve combination therapies that can work synergistically on common pathways. Going forward, innovative treatment strategies involving nanotechnology, young blood products transfusion and photobiomodulation also offer promise for the future.
目前尚无治愈阿尔茨海默病(AD)的方法。一种解释可能与需要尽早从β-淀粉样斑块和tau 缠结的积累上游进行干预有关。
完成了一项 PubMed 文献检索,以综述疾病起始基础上的生物学或病理学变化;这包括神经炎症、氧化应激、微生物组变化和糖质系统功能障碍。还讨论了基于这些机制的创新治疗策略。
更好地了解 AD 背后的病理生理机制将有助于确定临床试验的药物靶点。此外,药代动力学和药效动力学研究是描述疾病修饰药物特性和提高其穿透血脑屏障能力的关键。可以在疾病的不同阶段检查药物靶点,因此选择和招募合适的参与者(最好是在 AD 的早期阶段)非常重要。应该建立新的试验设计,主要涉及联合治疗,这些治疗可以在共同途径上协同作用。未来,涉及纳米技术、年轻血液制品输注和光生物调节的创新治疗策略也具有广阔的前景。